A cutting-edge biopharmaceutical company that targets rare and orphan diseases said it has submitted an application to the U.S. Food and Drug Administration requesting approval for a potentially revolutionary drug to treat sickle cell disease.
A cutting-edge biopharmaceutical company that targets rare and orphan diseases said it has submitted an application to the U.S. Food and Drug Administration requesting approval for a potentially revolutionary drug to treat sickle cell disease.